Key findings

  • 0.25 and 0.5 mg/kgGBR12909 doses that significantly increased accuracy of low-attentive rats versus vehicle (all p < 0.01)
  • F (3,33) = 9.782, p < 0.0001Group x Treatment interaction for accuracy; vehicle high-attentive rats were more accurate than vehicle low-attentive rats
  • 7 out of 22rats whose accuracy improved after 0.25 and 0.5 mg/kg GBR12909; those with baseline accuracy < 85% benefited the most

Abstract

Stimulants such as methylphenidate are the first-line treatment for attention deficit hyperactivity disorder. A principal mechanism of action for these drugs is to reduce dopamine reuptake in the striatum. However, the ensuing risk of abuse with such stimulants means there is an urgent need for new, low-risk therapeutic agents. GBR12909 is a highly selective dopamine reuptake inhibitor, making it an important experimental tool. Indeed, this drug completed Phase II clinical trials for treatment of cocaine abuse. Researching the behavioural pharmacology of such drugs has the potential to expand our understanding of the striatal dopamine contribution to impulsivity, attention and compulsive behaviour and will help the development of novel targeted treatments for attention deficit hyperactivity disorder without an abuse risk. The aim of this work was to examine the role of low doses of GBR12909 on attention, impulsivity and compulsive behaviour as measured by the five-choice continuous performance task. Oldham’s method was used to determine the presence of a treatment rate-dependent effect. Female Lister hooded rats were trained to criterion in the five-choice continuous performance task (>70% accuracy, <30% omission and <40% false alarms). The effects of GBR12909 (dose range 0.25-1.0 mg/kg) were investigated on attention, impulsivity and compulsive behaviour under challenging task conditions. The two lowest doses of GBR12909 improved selective attention in a rate-dependent manner while the highest dose of GBR 12909 showed a tendency toward improving compulsive behaviour in a baseline-dependent manner. However, GBR 12909 impaired waiting impulsivity in a baseline-dependent manner. GBR12909 has a clearly beneficial effect on attention and compulsive behaviour in the female rat. This study supports a contribution of the dopaminergic system in modulating five-choice continuous performance task performance measures. It provides evidence for the role of a selective dopamine reuptake inhibitor in modulating selective attention and inhibitory response control in the five-choice continuous performance task. Understanding the contribution of DAT to waiting impulsivity, selective attention and compulsive behaviour may help the development of selective therapeutic agents. Although group performance revealed no significant change in selective attention and compulsive behaviour, Oldham’s method revealed a latent relationship between baseline compulsivity or accuracy and magnitude of improvement following selective activation of dopaminergic system. It is clear from these results that the effectiveness of GBR 12909 in improving selective attention and compulsive behaviour is dependent on dopaminergic system baseline activity. In this study, Oldham method revealed a relationship that would have otherwise gone unnoticed. The clockwise movement of the regression line indicates that, as the dose increases, the magnitude of improvement increases in a manner consistent with baseline performance. These findings support further clinical investigation of GBR-type dopamine uptake blockers or GBR analogues to facilitate the discovery of medications for inattentive subtype of attention deficit hyperactivity disorder, stimulant abuse, compulsive drug seeking behaviour and obsessive-compulsive disorder. The concept of rate dependency applies to effects of GBR 12909 on waiting impulsivity, selective attention and compulsive behaviour. Oldham’s correlation method may present an opportunity to enhance the translational value of research in the preclinical laboratory to the clinic. This is the first study to take advantage of the variation in individual baseline performance to demonstrate the presence of a rate-dependent relationship between baseline performance and the magnitude of change following indirect activation of dopaminergic system. Adopting a correlative analysis (e.g., Oldham’s method) may be particularly effective in revealing drug effects on behaviour and improve our understanding of the neurochemical basis of selective attention, waiting impulsivity and compulsive behaviour as measured by five-choice continuous performance task. Future work can expand the current study, for example, five-choice continuous performance task has been reverse translated to human, enabling selective attention and compulsive behaviour to be studied in both patients and rodents

Introduction

Attention deficit hyperactivity disorder (ADHD) is a psychiatric disorder characterized by three main behavioural deficits in attention, hyperactivity and impulsivity1. These are observed during early childhood and often persist into adult life. Indeed, children diagnosed with ADHD have a higher risk of developing social and cognitive problems in later life2. The prevalence of ADHD is between 2-7%: 5% of children have difficulties with inattention and hyperactivity and 2-4% of adults are diagnosed with ADHD3. With increasing age, inattention becomes more prominent while impulsivity diminishes4,5. Depending on the main symptoms, ADHD can be divided into three categories: lack of attention (most prevalent among girls), hyperactivity (more prevalent among boys) and a third subtype that is a combination of the first two7. ADHD is more common in males than in females; however, ADHD is unrecognised and underdiagnosed in many countries. Thus, in the UK, less than 50% of children with inattention and hyperactivity have been diagnosed with ADHD4 and Females may also go underdiagnosed because they tend to have inattentive traits (less noticeable symptoms) rather than impulsive traits4. In addition, coexisting anxiety and depression in females with ADHD may lead to missed diagnoses7.

Stimulants such as methylphenidate and amphetamine are the most common pharmacological treatments for ADHD1. However, these have the potential to lead to abuse and dependence8. For example, stimulants (‘smart pills’) are commonly used by students to enhance academic performance9. Non-stimulants (such as atomoxetine and guanfacine) are the second-line treatment for ADHD; however, these are less effective than stimulants and have a delayed onset of action. Therefore, there is a pressing need for new therapeutic agents that have high efficacy but act without this dependence potential9. Many theories have been developed to explain the behavioural deficit in ADHD, with the most widely accepted mechanism being a deficit in dopaminergic neurotransmission as standard ADHD medications are indirect-acting dopaminergic receptor agonists4. Researchers have focused on dopamine because in healthy individuals it has a very important role in attention, behaviour and reward9,10,11,12. The behavioural deficits in ADHD have been linked with hypofunction of the catecholaminergic system in brain regions associated with inattention and impulsivity1. Levels of synaptic dopamine are regulated by dopamine transporters (DAT) and it is thought that upregulation of the latter results in deficits in selective attention and motivation in patients with ADHD through decreased synaptic dopamine levels in brain areas such as the prefrontal cortex and striatum11,13.

The continuous performance test (CPT) is the standard clinical test for ADHD14,15. The rodent 5-choice version of CPT (5C-CPT) measures attention and impulsivity in a manner consistent with human CPT16,17,18,19,20,21. Indirect dopaminergic agonists such as amphetamine, methylphenidate and modafinil are widely used clinically to treat cognitive deficits in ADHD and these drugs have been used in preclinical studies to test predictive validity of the five-choice continuous performance task (5C-CPT)19,22,23,24,25. Recently, it has been reported that touchscreen 5C-CPT can reliably reveal a cognitive-enhancing effect of amphetamine in mice and human subjects, as systemic administration of amphetamine (a potent dopamine and noradrenaline reuptake inhibitor) under baseline (standard task demand) conditions improved vigilance by increasing hit rate (probability of a correct response) without affecting response inhibition (probability of a false alarm) and waiting impulsivity (premature response) in both species24. Subsequent studies showed that 5C-CPT can reveal a cognitive enhancing effect of methylphenidate or amphetamine in rats, highlighting the translational validity of this task in preclinical studies19,26. Furthermore, Modafinil, a weak dopamine and noradrenaline reuptake inhibitor, improved 5C-CPT performance in human subjects by increasing hit rate27. The effectiveness of standard ADHD medications in reversing attentional deficits in ADHD patients supports the importance of DAT inhibitors in improving attentional processes.

Recent pre-clinical studies have focused on binning rats into high- and low-performing subgroups, based on their baseline performance (rather than combining animals together), to investigate the effect of dopaminergic manipulation on attentional performance in each sub-group under challenging task conditions19,21. Rate dependence is a well-supported phenomenon in behavioural pharmacological studies, in which the effectiveness of pharmacological intervention changes in a manner consistent with baseline performance28. The most common type of rate-dependent function is an inverse relationship between baseline performance and the behavioural change following drug administration28,29. This type of relationship can be divided into three types: (1) full-range effect, in which low baseline values increase and high baseline values decrease; (2) limited low-range effect, in which low baseline values increase with small changes in high baseline values; (3) limited high-range effect, in which high baseline values decrease with a small change in low baseline values29. A less common type of rate-dependent relationship is a direct relationship between baseline and the change following intervention28. Analysis of rate-dependence is often used as a last resort when experimenters find no change in group performance. One of the reasons for this could be the statistical analysis used to determine the presence of a rate-dependent effect30. Traditionally, baseline dependency is determined by plotting baseline performance against the change following drug administration (‘Simple’ method). However, this type of relationship is affected by regression to the mean and mathematical coupling30. To control for these potential confounds the ‘Oldham’ method was developed to determine the presence of a rate-dependent effect29,31,32. Determining rate dependence is important as it helps to reveal a relationship that would have otherwise gone unnoticed. Previous studies report that low-impulsive group showed an increased stop signal response time (SSRT) following modafinil treatment while the high-impulsive group showed a decreased SSRT33. Re-analysing the data using individual scores showed an inverse relationship between placebo baseline SSRT and the proportion of change in SSRT following modafinil administration, that is, rate-dependence29.

Understanding the effects of selective DAT inhibitors on attention and impulsivity in a task with high translational validity may help the development of novel targeted treatments without an inherent abuse and dependence risk. Contrary to other indirectly acting dopaminergic agonists such as amphetamine and methylphenidate, GBR12909 is a highly selective dopamine reuptake inhibitor, making it an interesting experimental tool8,. It would be insightful to investigate the effect of a selective DAT inhibitor on a task with high translational validity to humans, such as 5C-CPT17,19, to determine whether improvement in signal detection is due to improved attention or response inhibition and if there is a correlation between baseline 5C-CPT measures and magnitude of change after drug administration. Understanding the contribution of DAT to waiting impulsivity and selective attention may help the development of selective therapeutic agents. For this reason, we investigated the role of a selective DAT inhibitor in modulating attentional processes and inhibitory response control as measured by 5C-CPT. As the Oldham method helps in revealing baseline-dependent effects of stimulants on waiting impulsivity29 we used correlational analyses to account for natural variation in baseline data when evaluating the effectiveness of GBR 12909 on 5C-CPT performance measures. We compared the traditional method of presenting data with correlational analysis using Oldham’s method to determine if this drug modulates performance measures in a rate-dependent manner.

Materials and Methods

Animals

Female Lister hooded rats (n=22; Charles River, UK) were housed in groups of 5 in a temperature (21 ± 2 °C) and humidity (55±5%) controlled environment (University of Manchester BSF facility). Rats weighed 230±10g upon arrival and were allowed free access to food (Special Diet Services, UK) and water for one week prior to the beginning of training. Home cages were individually ventilated cages with two levels (GR1800 Double-Decker Cage, Techniplast, UK) and testing was completed under a standard 12-hour light: dark cycle (lights on at 7:00 am). Two days before training commenced food restriction was initiated to encourage their task engagement and this continued throughout training. During training rats were maintained at approximately 90% of their free-feeding body weight (fed 10 g rat chow/rat/day) and were provided with free access to water. All procedures were conducted in accordance with the UK animals (Scientific Procedures) 1986 Act and local University ethical guidelines.

Rat five-choice continuous performance task apparatus

Training took place in 8 operant chambers (Campden instruments Ltd, UK), each placed inside a ventilated and sound-attenuating box. The chambers were of aluminium construction 25cm × 25 cm. Each chamber had a curved wall containing nine apertures. For 5C-CPT training, four of the apertures were blocked by metal caps while the other five were left open (numbers 1, 3, 5, 7 and 9). Each aperture had a light and an infrared beam crossing its entrance to record beam breaks following nose poke. A reward dispenser was located outside each chamber to automatically dispense reinforcers (45 mg sucrose food pellets; Rodent Pellet, Sandown Scientific, UK) into a food tray at the front of the chamber. Entrance to each food tray was covered by a hinged panel so that tray entries were recorded when the rat’s snout opened the panel. House lights were placed in the side wall of the chambers and performance was monitored by a camera attached to the roof.

Five-choice continuous performance task behavioural training

The 5C-CPT benefits from non-target trials in which all five holes are lit and the rat must not respond at any of the five reward positions16,17. The incorporation of non-target trials helps to dissociate response inhibition from waiting impulsivity; premature responses during target trials reflect a deficit in waiting impulsivity, while the failure to withhold responding (false alarms) during non-target trials represents response disinhibition16,17. This task also allows the assessment of vigilance in rodents in a manner consistent with human CPT using signal detection theory, facilitating translation of rodent outcomes to the clinic34. Training was conducted in a similar manner to previous studies using 5C-CPT19.

Signal detection theory

Two primary parameters are calculated from 5C-CPT trial-outcome measures. The first is hit rate and the second is false alarm rate16,17. From these two parameters, sensitivity (vigilance) and bias can be calculated using SDT (see Table 1). Sensitivity reflects the ability to respond to the illuminated hole and inhibit that prepotent response when all five holes are illuminated. Sensitivity can also be measured non-parametrically by calculating the sensitivity Index17,35. 5C-CPT performance can also be affected by bias (tendency to respond to stimuli), which can be measured by calculating the responsivity index (RI)34.

Table 1. Parameters generated from 5C-CPT trials. Hit = correct response, Miss = omission, CR = correct rejection, FA = false alarm, FAR = false alarm rate, HR = hit rate, d’ = discriminability index, SI= sensitivity index and RI = responsivity index.

Trial TypeMeasureCalculationsSDT parameters
Target trialsHit and MissHR = Hit / (Hit + Miss)SI = (HR−FAR) / (2(HR+FAR)−(HR+FAR)2)
Non-target trialsCR and FAFAR = FA / (FA + CR)RI = (HR + FAR − 1) / (1 − (FAR − HR)2)

Experimental design

Drug preparation. GBR 12909 dihydrochloride was purchased from Sigma (UK) and dissolved in distilled water. Drug was freshly prepared each day before testing and was injected via the intraperitoneal (i.p.) route 20 min before behavioural testing at a dose volume of 1 ml/kg. All drug doses were calculated as base equivalent weight. The doses used in this study were chosen based on previous studies in rats utilising 5-choice serial reaction time task (5-CSRTT)36.

Behavioural testing. Twenty-two rats were used to investigate the effect of GBR12909 on 5C-CPT performance using challenging task conditions that consisted of a variable inter-trial interval (8, 9, 10, 11 and 12 s) and a variable stimulus duration (SD: 1, 0.75 and 0.5 s). The session lasted no longer than 60 min. The inter-trial interval (ITI) was increased to provoke impulsive behaviour. Using a within-subject design rats received 0.25, 0.5, 1mg/kg GBR or vehicle, 20 min before the task. All animals received a standard training session between the testing sessions to ensure performance was maintained at a stable baseline. Each test day was followed by at least a 7-day washout period, after which behavioural testing re-commenced. Prior to the first test day, all animals had been habituated twice to i.p. saline injections.

Statistical analysis. All data are displayed as observed mean ± SEM. Overall performance was analysed by one-way repeated measures ANOVA followed by Planned Comparisons. Analysis of the performance across the duration of the session was carried out by two-way repeated measures ANOVA (Trial and treatment as within-subject factors) followed by Planned Comparison on the predicted means. If the outcome of the repeated-measures ANOVA yielded significant effects of dose, further post-hoc analysis was performed using Dunnett multiple comparison test. Alpha level was set to 0.05 and all analysis was carried out using GraphPad Prism (v9.0).

Correlational analysis. This study investigated if baseline performance predicted the degree of change in performance following administration of GBR using Oldham method. Oldham’s method was used to determine the presence of a rate dependent relationship. Pearson’s correlation was used when individuals were normally distributed. Nonparametric Spearman’s correlation was used when individuals were not normally distributed. Oldham’s r > 0.3 indicates the presence of a rate dependent relationship29,31,32,37. An outlier may increase the value of r, therefore, Grubbs test was used to detect an outlier. Correlations were deemed significant when r≥ 0.49 (G*Power 3.1; alpha=0.05, power=0.8; n=22).

Results

Effect of GBR 12909 on waiting impulsivity as measured by 5C-CPT performance

The main effect of GBR 12909 on motoric impulsivity averaged across different ITI is shown in Fig. 1A. GBR 12909 showed a tendency towards increasing premature responding. One-way repeated measures ANOVA revealed no significant treatment effect [F (2.712, 56.95) = 2.320, P=0.0908]. Correlational analyses are shown in Fig. 1B. The Oldham method revealed a positive association between baseline impulsivity and magnitude of change following administration of all GBR doses, indicative of a rate dependent effect.

Figure 1. Effects of GBR 12909 (0.25, 0.5 or 1 mg/kg) on waiting impulsivity of rats tested under variable ITIs and variable SDs (n=22). (A) Group impulsivity performance. (B) Correlational analysis (Oldham’s method). Measures are shown as observed mean ±SEM.

Within-session performance (waiting impulsivity and motivation)

The session consisted of 209 trials broken into 7 blocks, where each block consisted of 30 trials (Fig. 2A). A two-way repeated measures ANOVA approach revealed a significant trial [F (2.972, 62.42) = 12.88, P < 0.0001] and treatment effect [F (2.691, 56.51) = 2.942, P < 0.05] on impulsivity. Dunnett tests revealed a significant decrease in number of baseline premature responses in fourth (P< 0.05), sixth (P< 0.01) or seventh (P< 0.01) trial block compared with first trial block, indicative of improvement in waiting impulsivity over time. Dunnett tests also showed that the highest dose of GBR increased waiting impulsivity in the second (P< 0.05), fourth (P< 0.05) and sixth (P< 0.01) trial block compared with control of the same block. The intermediate dose of GBR increased waiting impulsivity in the fifth trial block (P< 0.05) when compared with control of the same block. The gradual decrease in baseline waiting impulsivity as the session progresses could be due to change in motivation (Responsivity index), therefore, waiting impulsivity across the session was compared with responsivity across the session. Effects of GBR on responsivity index (motivation) over the course of the session is shown in Fig. 2B. A two-way repeated measures ANOVA approach revealed a significant trial effect [F (6, 592) = 3.228, P < 0.01] and no significant treatment effect [F (3, 592) = 1.973, P = 0.116] on responsivity index. Decrease in baseline responsivity index is indicative of waning motivation over the course of the session. Dunnett tests revealed a significant decrease in responsivity of 0.5 mg/kg treated rats in sixth trial block compared with 0.5 mg/kg GBR treated rats in the first trial block (P< 0.05), indicative of waning motivation. By comparing pattern between baseline premature responses and baseline responsivity index, the decrease in baseline premature response at the end of the session (trial block 7) can be determined to result not from waning motivation, but from learning mechanism (improvement in inhibitory response control over the course of the session).

Figure 2. Effects of GBR 12909 on impulsivity or responsivity index across the session (n=22). (A) Effects of GBR on impulsivity. (B) Effects of GBR on responsivity index. Measures are shown as observed mean ±SEM. +p < 0.05 and ++ p < 0.01 compared to control or GBR treated rats of 1st trial block. * p < 0.05 and ** p < 0.01, compared to control of the same block.

Effect of GBR12909 on selective attention (accuracy) and omission

Main effect of GBR 12909 on attentional accuracy and omission averaged across different ITI is shown in Fig. 3A. Repeated measures one-way ANOVA revealed no significant treatment effect on accuracy [F (2.109, 44.29) = 2.713, P=0.07] and omission [F (2.741, 57.56) = 1.03, P=0.38]. Variability in baseline attentional performance was observed in individual animals and was used to divide rats into three subgroups. Rats were split into high-attentive (HA), mid attentive (MA) and low-attentive (LA) subgroups based on accuracy and number of misses made after saline administration (Fig. 3B). Previous studies report no significant change in the performance of mid attentive rats following drug administration21. Previous studies used an upper lower quartile split (excluded the mid attentive rats)21. The exclusion of mid attentive rats resulted in a larger separation between HA and LA subgroups. Therefore, in this study the mid attentive rats were excluded from the analysis. Only the HA (accuracy > 95% and omission < 50%) and LA rats (accuracy < 80% and omission > 50%) were included in the analysis. Effects of GBR 12909 on accuracy and omission of HA and LA rats are shown in Fig 3B. A repeated measure two-way ANOVA revealed a Group x Treatment interaction for accuracy [F (3,33) = 9.782, p< 0.0001]. Accuracy was significantly higher in vehicle HA rats compared with vehicle LA rats (p< 0.0001). Dunnett’s test revealed that GBR significantly increased accuracy of LA rats at 0.25 and 0.5 mg/kg (all p<0.01) compared with vehicle control. GBR also reduced accuracy of HA rats at 0.25 mg/kg compared with vehicle control (p<0.05). A repeated measure two-way ANOVA revealed no Group x Treatment interaction for omission [F (3, 33) = 0.8443, P=0.47]. Re-analysis of the data using Oldham method revealed that the magnitude of improvement following administration of 0.25mg/kg and 0.5mg/kg GBR12909 was dependent on baseline accuracy (correlation analysis is shown in Fig. 3C). Oldham method’ revealed a strong negative association between baseline accuracy and the change following 0.25 mg/kg GBR and a moderate negative association between baseline accuracy and the change following 0.5 mg/kg GBR. Improved accuracy was seen in 7 out of 22 rats following 0.25 and 0.5 mg/kg GBR; rats with baseline accuracy < 85 % benefited the most from this treatment.

Figure 3. Effects of GBR12909 on performance accuracy and omission (n=22). (A) Group performance. (B) Subgroup performance. (C) Correlational analysis. Measures are shown as observed mean ±SEM. *p < 0.05, ** p < 0.01 compared to control of the same group. ++++p < 0.0001 compared to control of LA rats (Dunnett).

Effects of GBR on compulsive behaviour

The main effect of GBR on compulsive behaviour is shown in Fig. 4 (A-C). GBR showed a tendency to decrease perseverative responding during target trials, although this did not reach significance [F (1.111, 23.33) = 1.088, P=0.3153]. In addition, GBR produced no significant change in perseverative responding when the number of perseverative responses during target and non-target trials was combined [F (1.239, 26.01) = 1.031, P=0.3364]. The highest dose of GBR showed a tendency toward reducing compulsivity in a manner consistent with baseline performance, however, it did not reach a significant level (Fig 4). Grubbs’ test did not detect an outlier. Relationship between baseline Perseverative correct response or Perseverative false alarm and magnitude of change following administration of GBR (0.25, 0.5 or 1 mg/kg) is shown in Supplement Table 4.

Figure 4. Effects of GBR on perseverative responding in the 5C-CPT. Effects of GBR on (A) perseverative correct responses, (B) perseverative false alarms, and (C) total number of perseverative responses. (D) Relationship between baseline compulsivity and magnitude of improvement following administration GBR. PER= perseverative responses.

Measurements of Oldham’s angles

Amount of space between the regression lines were measured using a protractor. Three angles were measured: A, B and C as shown in Fig 5. Oldham’s angle measurements for the relationship between baseline accuracy and GBR induced change are shown in Fig 5A. A is the space between 1 mg/kg and 0.25 mg/kg regression lines. B is the space between 1 mg/kg and 0.5 mg/kg regression lines. C is the space between 0.5 mg/kg and 0.25 mg/kg lines (Fig 5A). If two angles are known, then the third angle can be calculated. For example, B=A+C. The measurement of the angle and the direction of movement (clockwise or counterclockwise) shows how effective is one dose at increasing accuracy of low attentive rats and reducing accuracy of high attentive rats compared with other doses. Oldham’s angle measurements for the relationship between baseline perseverative responses and GBR induced change are shown in Fig 5B-C. A is the space between the highest and the lowest dose (1 mg/kg and 0.25 mg/kg regression lines). B is the space between the highest and the intermediate dose (1 mg/kg and 0.5 mg/kg regression lines). C is the space between 0.5 mg/kg and 0.25 mg/kg lines (Fig 5B). If two angles are known, then the third angle can be calculated. A=B+C (Fig 5B-C). The clockwise movement (⟳) of the regression line as the dose increases shows that the highest dose is more effective than the lowest or the intermediate dose at reducing compulsive behaviour.

Figure 5. Measurement of Oldham’s angles. (A) Correlation between baseline accuracy and GBR induced change. (B) Correlation between baseline perseverative responses and GBR induced change. (C) Correlation between baseline perseverative correct responses and GBR induced change. Arrows show the clockwise movement of the regression line.

Discussion

The current study highlights a preclinical approach to help address the pressing need for new ADHD medications that lack the treatment dependence issues seen with currently prescribed medications. Here, we examined the effects of the DAT antagonist GBR 12909 on 5C-CPT performance measures using the Oldham method in female Lister Hooded rats. Examination of the effect of this compound showed that the selective inhibition of DAT changes 5C-CPT performance measures in a rate-dependent manner. All doses of GBR changed waiting impulsivity in a baseline-dependent manner and the two lowest doses of GBR changed accuracy in a baseline-dependent manner. The highest dose of GBR showed a tendency toward changing compulsive behaviour in a rate-dependent manner. Taken together, the present results indicate that low doses of GBR improve accuracy of low-attentive rats and improve compulsivity in high-compulsive rats.

There is strong evidence to link DAT inhibition with inhibitory response control and visuospatial attention in rats11,13,38. The selective DAT inhibitor GBR12909 has been consistently reported to increase premature responding in the 5-CSRTT36,39. For example, moderate doses of GBR12909 (2.5 and 5 mg/kg) impaired waiting impulsivity in high-impulsive rats; however, this impairment did not reach statistical significance36. In another 5-CSRT study, a higher dose of GBR12909 (10 mg/kg) caused a significant increase in the number of premature responses under standard and challenging test conditions (long ITI)39. In the current study, systemic treatment with low doses of GBR12909 (0.25-1 mg/kg) impaired waiting impulsivity in a baseline dependent manner, further supporting a role for the dopamine transporter in regulating inhibitory response control as measured by 5C-CPT. The effect of GBR12909 on impulsivity is likely due to an increase in dopamine levels in subcortical regions, most likely the striatum38 . Correlation analysis using Oldham’s method revealed a direct relationship between baseline impulsivity and the change following GBR12909. A greater increase in impulsivity was observed in rats with high baseline impulsivity. The current study is the first to establish the presence of a rate-dependent relationship between baseline impulsivity and the change following GBR 12909. A within-session learning effect has previously been reported in studies using an extended ITI challenge with a constant SD35. By comparing patterns between waiting impulsivity and motivation (responsivity index), the decrease in baseline waiting impulsivity at the last trial block can be determined to result not from waning motivation, but from learning mechanism (improvement in inhibitory response control over the course of the session). Evidence for GBR-induced impairment in waiting impulsivity was observed when performance was examined across the session. GBR 12909 caused a dose dependent increase in waiting impulsivity, persisting until the end of the session. A statistically significant increase in waiting impulsivity following administration of the highest dose of GBR 12909 was observed after the first trial block. The impairment of waiting impulsivity was most substantial during the 6th trial block. This finding is consistent with previous studies reporting that systemic administration of GBR12909 (0.75 and 0.5 mg/kg) induces a significant DAT inhibition in rats within a matter of seconds, with dopamine uptake inhibition peaking 10-15 minutes post dosing.

Alongside the effect of GBR on waiting impulsivity, GBR (at 0.25 and 0.5 mg/kg) improved accuracy in low-attentive (LA) rats. Oldham’s method revealed an orderly relationship between baseline accuracy and response to GBR12909. In other words, the two lowest doses of GBR improved accuracy in rats with low baseline accuracy, but impaired accuracy in rats with high baseline accuracy, further supporting the inverted U function of dopaminergic activation in impulsivity19,29. The pro-cognitive effect of GBR 12909 on attentional accuracy in the present study is consistent with the pro-cognitive effect of stimulants (which target DAT) in the signal detection task23. The signal detection task is different from 5 choice tasks in that the rodent is required to detect a target visual stimulus presented repeatedly in the same location (central panel) rather than detecting a stimulus that may appear in any one of five locations23,40. Recently the signal detection task has been used to examine the relationship between baseline accuracy and proportion of change in accuracy following amphetamine administration40. Administration of a low dose of amphetamine improved attention by altering accuracy in low-attentive rats and this improvement correlated negatively with baseline accuracy performance40. Correlational analysis using the re-test reliability method revealed a moderate negative association between baseline accuracy and the change following administration of amphetamine23. These data demonstrated an increase in low baseline accuracy and a decrease in high baseline accuracy (Full range effect). Therefore, the effect of pharmacological manipulation on accuracy is dependent on heterogeneity of the performance prior to manipulation (baseline performance)29. This study further confirmed the importance of dopamine in attentional processes by suggesting that the attentional impairment observed in low-performing rats could be due to dysregulation of the dopaminergic system23 .However, the signal detection task is limited in that it does not include non-target trials, therefore, it cannot be used to measure response inhibition and sustained attention in a manner consistent with human CPT23,40.The pro-cognitive effect of GBR 12909 on attentional accuracy in the present study is consistent with pro-cognitive effect of stimulants (which target DAT) in clinical studies41,42. This is the first study to report the pro-cognitive effect of low doses of GBR, which was not revealed in previous studies36 The observation of such an effect here is likely because previous studies did not examine the relationship between baseline performance measures and the change following GBR12909 administration. Thus, correlational analysis used in this study were vital in revealing a relationship that would otherwise have gone unnoticed.

Dopaminergic neurotransmission in the NAcb has also been associated with compulsive drug seeking behaviour43. In the present study, the highest dose of GBR 12909 showed a tendency toward improving perseverative correct response and total number of perseverative responses in a baseline dependent manner. This is the first study to report the presence of a negative relationship between baseline compulsivity and magnitude of change following administration of GBR 12909, suggesting that baseline levels of compulsive behaviour may influence the GBR 12909 effect. Thus, rats with high baseline compulsivity benefited the most from the treatment. This finding is consistent with previous studies in mice performing the Iowa gambling task (IGT), which report a decrease in perseverative responses following administration of GBR 1290944. In addition, the abuse potential of amphetamine has been linked with its action on the mesolimbic dopaminergic pathway, and it has been reported that GBR 12909 may be effective for the treatment of stimulant addiction8. Subjects using cocaine are at increased risk of obsessive-compulsive disorder (OCD)45 and there is an elevated risk of developing substance abuse in subjects with existing OCD46 . As the main symptoms of OCD are perseveration and indecision47, OCD is more prevalent among females in adolescence and adulthood and 40% of patients with OCD do not respond to current medications47,48. The clinical investigation of novel analogues of GBR may well facilitate the discovery of new therapeutic agents for OCD. Future work can expand the current study, for example, 5C-CPT has been reverse translated to human, enabling compulsive behaviour to be studied in both OCD patients and rodents34. Together, these findings suggest that 5C-CPT can be used to measure impulsive and compulsive behaviour and these behaviours are independent.

In conclusion, the two lowest doses of GBR improved accuracy in female rats with low baseline accuracy, but impaired accuracy in female rats with high baseline accuracy, further supporting the inverted U function of dopaminergic activation in impulsivity. The highest dose of GBR 12909 showed a tendency toward improving compulsive behaviour in a baseline dependent manner. Rats with high baseline compulsivity benefited the most from the treatment. Unlike effects of GBR 12909 on selective attention and compulsive behaviour, GBR impaired impulsive behaviour in a baseline dependent manner. This study also highlights the value of Oldham’s method in revealing baseline-dependent effects of drugs on inhibitory response control and cognitive function in 5C-CPT. This study suggests that pre-drug baseline performance can influence the change from baseline following administration of GBR 12909 in rats. These findings suggest that activation of dopaminergic system improves selective attention and compulsive behaviour. Novel analogues of GBR-type dopamine uptake blockers (GBR 12909 and GBR 12935) may have clinical utility for the treatment of obsessive-compulsive disorder, obsessive drug seeking behaviour, substance abuse in subject with existing OCD and inattentive subtype of ADHD (more prevalent among girls and adults).

This study supports a contribution of the dopaminergic system in modulating 5C-CPT performance measures. It provides evidence for the role of a selective dopamine reuptake inhibitor in modulating selective attention and inhibitory response control in the 5C-CPT. Understanding the contribution of DAT to waiting impulsivity and selective attention may help the development of selective therapeutic agents. In particular, this study suggests that pre-drug baseline performance can influence the change from baseline following administration of GBR in rat. Additional experiments are required to further explore rate-dependent effects of GBR on other measures of 5C-CPT such as sustained attention and response inhibition. Although group performance revealed no significant change in selective attention and compulsive behaviour, Oldham’s method revealed a latent relationship between baseline compulsivity or accuracy and magnitude of improvement following selective activation of dopaminergic system. This study supports a contribution of the dopaminergic system in modulating 5C-CPT performance measures. It provides evidence for the role of a selective dopamine reuptake inhibitor in modulating selective attention and inhibitory response control in the 5C-CPT. This study is the first demonstration of improved selective attention and compulsive behaviour after selective activation of dopaminergic system in 5C-CPT. In this study, Oldham method revealed a relationship that would have otherwise gone unnoticed. The clockwise movement of the regression line indicates that, as the dose increases, the magnitude of improvement increases in a manner consistent with baseline performance. The concept of rate dependency applies to effects of GBR 12909 on waiting impulsivity, selective attention and compulsive behaviour. Oldham’s correlation method may present an opportunity to enhance the translational value of research in the preclinical laboratory to the clinic. This is the first study to take advantage of the variation in individual baseline performance to demonstrate the presence of a rate-dependent relationship between baseline performance and the magnitude of change following indirect activation of dopaminergic system. Adopting a correlative analysis (e.g., Oldham’s method) may be particularly effective in revealing drug effects on behaviour and improve our understanding of the neurochemical basis of selective attention, waiting impulsivity and compulsive behaviour as measured by 5C-CPT. Future work can expand the current study, for example, 5C-CPT has been reverse translated to human, enabling selective attention and compulsive behaviour to be studied in both ADHD patients and rodents

Declarations

Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Data Availability Statement
The authors declare that all the data supporting the findings of this study are available within the paper and its Supplemental Data.
Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References

  1. Mueller A, Hong DS, Shepard S, Moore T. Linking ADHD to the Neural Circuitry of Attention. Trends Cogn Sci. 2017;21(6):474-488. doi:10.1016/j.tics.2017.03.009
  2. Lara C, Fayyad J, de Graaf R, et al. Childhood predictors of adult attention-deficit/hyperactivity disorder: results from the World Health Organization World Mental Health Survey Initiative. Biol Psychiatry. 2009;65(1):46-54. doi:10.1016/j.biopsych.2008.10.005
  3. Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry. 2018;5(2):175-186. doi:10.1016/S2215-0366(17)30167-0
  4. Faraone SV, Bellgrove MA, Brikell I, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2024;10(1):11. Published 2024 Feb 22. doi:10.1038/s41572-024-00495-0
  5. Telzer EH. Dopaminergic reward sensitivity can promote adolescent health: A new perspective on the mechanism of ventral striatum activation. Dev Cogn Neurosci. 2016;17:57-67. doi:10.1016/j.dcn.2015.10.010
  6. Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. J Am Acad Child Adolesc Psychiatry. 2000;39(11):1424-1431. doi:10.1097/00004583-200011000-00017
  7. Quinn PO, Madhoo M. A review of attention-deficit/hyperactivity disorder in women and girls: uncovering this hidden diagnosis. Prim Care Companion CNS Disord. 2014;16(3):PCC.13r01596. doi:10.4088/PCC.13r0159
  8. Ahn S, Phillips AG. Daily monitoring of dopamine efflux reveals a short-lasting occlusion of the dopamine agonist properties of d-amphetamine by dopamine transporter blockers GBR 12909 and methylphenidate. ACS Chem Neurosci. 2013;4(5):817-824. doi:10.1021/cn400040r
  9. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48(2):209-225. doi:10.1177/1060028013510699
  10. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett. 2000;285(2):107-110. doi:10.1016/s0304-3940(00)01040-5
  11. Volkow ND, Wang GJ, Newcorn J, et al. Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. Neuroimage. 2007;34(3):1182-1190. doi:10.1016/j.neuroimage.2006.10.014
  12. Bush G. Attention-deficit/hyperactivity disorder and attention networks. Neuropsychopharmacology. 2010;35(1):278-300. doi:10.1038/npp.2009.120
  13. Rubia K, Halari R, Cubillo A, et al. Methylphenidate normalizes fronto-striatal underactivation during interference inhibition in medication-naïve boys with attention-deficit hyperactivity disorder. Neuropsychopharmacology. 2011;36(8):1575-1586. doi:10.1038/npp.2011.30
  14. ROSVOLD, H. E., MIRSKY, A. F., SARASON, I., BRANSOME, E. B., & BECK, L. H. 1956. A continuous performance test of brain damage. Journal of Consulting and clinical Psychology 20,343–350
  15. Albrecht B, Uebel-von Sandersleben H, Gevensleben H, Rothenberger A. Pathophysiology of ADHD and associated problems-starting points for NF interventions? Front Hum Neurosci. 2015;9:359. Published 2015 Jun 24. doi:10.3389/fnhum.2015.00359
  16. Young JW, Light GA, Marston HM, Sharp R, Geyer MA. The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One. 2009;4(1):e4227. doi:10.1371/journal.pone.0004227
  17. Barnes SA, Young JW, Neill JC. D₁ receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test. Psychopharmacology (Berl). 2012;220(1):129-141. doi:10.1007/s00213-011-2460-8
  18. van Enkhuizen J, Acheson D, Risbrough V, Drummond S, Geyer MA, Young JW. Sleep deprivation impairs performance in the 5-choice continuous performance test: similarities between humans and mice. Behav Brain Res. 2014;261:40-48. doi:10.1016/j.bbr.2013.12.003
  19. Tomlinson A, Grayson B, Marsh S, et al. Pay attention to impulsivity: modelling low attentive and high impulsive subtypes of adult ADHD in the 5-choice continuous performance task (5C-CPT) in female rats. Eur Neuropsychopharmacol. 2014;24(8):1371-1380. doi:10.1016/j.euroneuro.2014.04.008
  20. Tomlinson A, Grayson B, Marsh S, Hayward A, Marshall KM, Neill JC. Putative therapeutic targets for symptom subtypes of adult ADHD: D4 receptor agonism and COMT inhibition improve attention and response inhibition in a novel translational animal model. Eur Neuropsychopharmacol. 2015;25(4):454-467. doi:10.1016/j.euroneuro.2014.11.016
  21. Hayward A, Tomlinson A, Neill JC. Low attentive and high impulsive rats: A translational animal model of ADHD and disorders of attention and impulse control. Pharmacol Ther. 2016;158:41-51. doi:10.1016/j.pharmthera.2015.11.010
  22. Grottick AJ, Higgins GA. Assessing a vigilance decrement in aged rats: effects of pre-feeding, task manipulation, and psychostimulants. Psychopharmacology (Berl). 2002;164(1):33-41. doi:10.1007/s00213-002-1174-3
  23. Turner KM, Peak J, Burne TH. Baseline-dependent effects of amphetamine on attention are associated with striatal dopamine metabolism. Sci Rep. 2017;7(1):297. Published 2017 Mar 22. doi:10.1038/s41598-017-00437-9
  24. MacQueen DA, Minassian A, Kenton JA, et al. Amphetamine improves mouse and human attention in the 5-choice continuous performance test. Neuropharmacology. 2018;138:87-96. doi:10.1016/j.neuropharm.2018.05.034
  25. Caballero-Puntiverio M, Lerdrup LS, Grupe M, Larsen CW, Dietz AG, Andreasen JT. Effect of ADHD medication in male C57BL/6J mice performing the rodent Continuous Performance Test. Psychopharmacology (Berl). 2019;236(6):1839-1851. doi:10.1007/s00213-019-5167-x
  26. Young JW, Roberts BZ, Breier M, Swerdlow NR. Amphetamine improves rat 5-choice continuous performance test (5C-CPT) irrespective of concurrent low-dose haloperidol treatment. Psychopharmacology (Berl). 2020;237(7):1959-1972. doi:10.1007/s00213-020-05511-1
  27. Cope ZA, Young JW. The Five-Choice Continuous Performance Task (5C-CPT): A Cross-Species Relevant Paradigm for Assessment of Vigilance and Response Inhibition in Rodents. Curr Protoc Neurosci. 2017;78:9.56.1-9.56.18. Published 2017 Jan 3. doi:10.1002/cpns.20
  28. Perkins KA. Baseline-dependency of nicotine effects: a review. Behav Pharmacol. 1999;10(6-7):597-615. doi:10.1097/00008877-199911000-00006
  29. Bickel WK, Quisenberry AJ, Snider SE. Does impulsivity change rate dependently following stimulant administration? A translational selective review and re-analysis. Psychopharmacology (Berl). 2016;233(1):1-18. doi:10.1007/s00213-015-4148-y
  30. Chiolero A, Paradis G, Rich B, Hanley JA. Assessing the Relationship between the Baseline Value of a Continuous Variable and Subsequent Change Over Time. Front Public Health. 2013;1:29. Published 2013 Aug 23. doi:10.3389/fpubh.2013.00029
  31. Snider SE, Quisenberry AJ, Bickel WK. Order in the absence of an effect: Identifying rate-dependent relationships. Behav Processes. 2016;127:18-24. doi:10.1016/j.beproc.2016.03.012
  32. Snider SE, Deshpande HU, Lisinski JM, Koffarnus MN, LaConte SM, Bickel WK. Working Memory Training Improves Alcohol Users' Episodic Future Thinking: A Rate-Dependent Analysis. Biol Psychiatry Cogn Neurosci Neuroimaging. 2018;3(2):160-167. doi:10.1016/j.bpsc.2017.11.002
  33. Zack M, Poulos CX. Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity. J Psychopharmacol. 2009;23(6):660-671. doi:10.1177/0269881108091072
  34. Young JW, Jentsch JD, Bussey TJ, Wallace TL, Hutcheson DM. Consideration of species differences in developing novel molecules as cognition enhancers. Neurosci Biobehav Rev. 2013;37(9 Pt B):2181-2193. doi:10.1016/j.neubiorev.2012.10.002
  35. Young JW, Powell SB, Scott CN, Zhou X, Geyer MA. The effect of reduced dopamine D4 receptor expression in the 5-choice continuous performance task: Separating response inhibition from premature responding. Behav Brain Res. 2011;222(1):183-192. doi:10.1016/j.bbr.2011.03.054
  36. Fernando AB, Economidou D, Theobald DE, et al. Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists. Psychopharmacology (Berl). 2012;219(2):341-352. doi:10.1007/s00213-011-2408-z
  37. OLDHAM PD. A note on the analysis of repeated measurements of the same subjects. J Chronic Dis. 1962;15:969-977. doi:10.1016/0021-9681(62)90116-9
  38. Dalley JW, Robbins TW. Fractionating impulsivity: neuropsychiatric implications. Nat Rev Neurosci. 2017;18(3):158-171. doi:10.1038/nrn.2017.8
  39. Baarendse PJ, Vanderschuren LJ. Dissociable effects of monoamine reuptake inhibitors on distinct forms of impulsive behavior in rats. Psychopharmacology (Berl). 2012;219(2):313-326. doi:10.1007/s00213-011-2576-x
  40. Turner KM, Peak J, Burne TH. Measuring Attention in Rodents: Comparison of a Modified Signal Detection Task and the 5-Choice Serial Reaction Time Task. Front Behav Neurosci. 2016;9:370. Published 2016 Jan 14. doi:10.3389/fnbeh.2015.00370
  41. Koelega HS. Stimulant drugs and vigilance performance: a review. Psychopharmacology (Berl). 1993;111(1):1-16. doi:10.1007/BF02257400
  42. Riccio CA, Reynolds CR, Lowe P, Moore JJ. The continuous performance test: a window on the neural substrates for attention?. Arch Clin Neuropsychol. 2002;17(3):235-272.
  43. Sanchez-Roige S, Peña-Oliver Y, Stephens DN. Measuring impulsivity in mice: the five-choice serial reaction time task. Psychopharmacology (Berl). 2012;219(2):253-270. doi:10.1007/s00213-011-2560-5
  44. van Enkhuizen J, Geyer MA, Young JW. Differential effects of dopamine transporter inhibitors in the rodent Iowa gambling task: relevance to mania. Psychopharmacology (Berl). 2013;225(3):661-674. doi:10.1007/s00213-012-2854-2
  45. Crum RM, Anthony JC. Cocaine use and other suspected risk factors for obsessive-compulsive disorder: a prospective study with data from the Epidemiologic Catchment Area surveys. Drug Alcohol Depend. 1993;31(3):281-295. doi:10.1016/0376-8716(93)90010-n
  46. Rowe C, Deledalle A, Boudoukha AH. Psychiatric comorbidities of obsessive-compulsive disorder: A series of systematic reviews and meta-analyses. J Clin Psychol. 2022;78(4):469-484. doi:10.1002/jclp.23240
  47. Miodownik C, Bergman J, Lerner PP, Kreinin A, Lerner V. Amisulpride as add-on treatment for resistant obsessive-compulsive disorder: retrospective case series. Clin Neuropharmacol. 2015;38(1):26-29. doi:10.1097/WNF.0000000000000065
  48. Mathes BM, Morabito DM, Schmidt NB. Epidemiological and Clinical Gender Differences in OCD. Curr Psychiatry Rep. 2019;21(5):36. Published 2019 Apr 23. doi:10.1007/s11920-019-1015-2

Article information

Authors

How to cite

Abdulkader, S., Neill, J., et al., 2026. The dopamine inhibitor GBR12909 improves attention and compulsive behaviour in female rats. Medical Research Archives, [online] 14(10). https://doi.org/10.18103/mra.2026.0712

Record

Journal
Medical Research Archives
Section
Research Articles
Published
31 October 2026
ISSN
2375-1924
Downloads
77

Copyright and licence

Published by the European Society of Medicine under a Creative Commons Attribution 4.0 International licence (CC BY 4.0), which permits unrestricted use, distribution and reproduction in any medium, provided the original authors and source are credited.